Publications

Title

Author

Year

Effective anti-tuberculosis therapy correlates with plasma small RNA.

Honeyborne, I; Lipman, MC; ECKOLD, C; Evangelopoulos, D; Gillespie, SH; Pym, A; McHugh, TD;

2015

The European respiratory journal, (2015).45 6 10.1183/09031936.00221214.

Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area.

Guerra-Assunção, JA; CRAMPIN, AC; HOUBEN, RM G J; MZEMBE, T; Mallard, K; COLL, F; KHAN, P; Banda, L; Chiwaya, A; Pereira, RP A; MCNERNEY, R; FINE, PE M; Parkhill, J; CLARK, TG; GLYNN, JR;

2015

eLife, (2015).4 4 10.7554/eLife.05166.

To improve our tuberculosis burden estimates we need to learn from each other.

HOUBEN, RM G J; WHITE, RG;

2015

The international journal of tuberculosis and lung disease, (2015).19 3 10.5588/ijtld.15.0037.

Regarding the effect of cured tuberculosis disease on longevity.

LALLI, M; HOUBEN, R; CHURCHYARD, G; WHITE, RG;

2015

The international journal of tuberculosis and lung disease, (2015).19 3 10.5588/ijtld.14.0852.

Multidrug resistant tuberculosis.

Millard, J; Ugarte-Gil, C; MOORE, DA J;

2015

BMJ (Clinical research ed), (2015).350 feb26 10.1136/bmj.h882.

The human immune response to tuberculosis and its treatment: a view from the blood.

CLIFF, JM; Kaufmann, SH E; McShane, H; Van Helden, P; O'Garra, A;

2015

Immunological reviews, (2015).264 1 10.1111/imr.12269.

Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus.

Ronacher, K; Joosten, SA; Van Crevel, R; DOCKRELL, HM; Walzl, G; Ottenhoff, TH M;

2015

Immunological reviews, (2015).264 1 10.1111/imr.12257.

Modelling the HIV epidemic among MSM in the United Kingdom: quantifying the contributions to HIV transmission to better inform prevention initiatives.

Punyacharoensin, N; EDMUNDS, WJ; De Angelis, D; Delpech, V; Hart, G; Elford, J; Brown, A; Gill, N; WHITE, RG;

2015

AIDS (London, England), (2015).29 3 10.1097/QAD.0000000000000525.

Coverage of clinic-based TB screening in South Africa may be low in key risk groups.

MCCREESH, N; Faghmous, I; Looker, C; Dodd, PJ; Plumb, ID; Shanaube, K; Muyoyeta, M; GODFREY-FAUSSETT, P; AYLES, H; WHITE, RG;

2015

Public health action, (2015).6 1 10.5588/pha.15.0064.

Drug-resistance mechanisms and tuberculosis drugs.

Köser, CU; Javid, B; Liddell, K; Ellington, MJ; Feuerriegel, S; Niemann, S; Brown, NM; Burman, WJ; Abubakar, I; Ismail, NA; MOORE, D; PEACOCK, SJ; Török, ME;

2015

Lancet, (2015).385 9965 10.1016/S0140-6736(14)62450-8.